If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
Response submitted within one month of FDA complete response letter KENILWORTH, N.J., Feb. Twenty (HSMN NewsFeed) — Schering-Plough Corporation (NYSE: SGP ) today announced that it has responded to the U.S. Food and Drug Administration (FDA) complete res…
Biopharmaceuticals
Schering-Plough, SAPHRIS, asenapine, schizophrenia
Posts from ‘February, 2009’
Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Neuralstem’s ALS Trial on Clinical Hold
ROCKVILLE, Md., Feb. 20 (HSMN NewsFeed) — Neuralstem, Inc. (NYSE Alternext US: CUR) announced today its spinal cord stem cell trial to treat ALS is on medical hold and that the Federal Drug Administration (FDA) has provided the Company with specific co…
Regenerative Medicine, Neurology
Neuralstem, stem cell, Amyotrophic Lateral Sclerosis
CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
SAN DIEGO, Feb. Nineteen (HSMN NewsFeed) — A new analysis from the JUPITER study presented today at the International Stroke Conference (ISC) in San Diego, California describes details of the stroke data according to gender, ethnicity and baseline risk factor…
Biopharmaceuticals
AstraZeneca, JUPITER study, CRESTOR, rosuvastatin
European Medicines Agency Recommends Suspension of Product management Authorization for Raptiva(R)
GENEVA, Switzerland, February Nineteen (HSMN NewsFeed) — Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the European Medicines Agency (EMEA) has recommended to the European Commission the suspension of the product management authoriza…
Biopharmaceuticals, Regulatory
Merck Serono, Merck KGaA, Raptiva, efalizumab, psoriasis
Gilead Receives Response From U.S. FDA on Company’s Request for Formal Dispute Resolution for Aztreonam for Inhalation Solution
FDA Reiterates Position of Complete Response Letter FOSTER TOWN, Calif.–(HSMN NewsFeed)–Gilead Sciences, Inc. (Nasdaq:GILD ) today announced that the company has received a response from the U.S. Food and Drug Administration (FDA) to its appeal, submi…
Biopharmaceuticals, Drug Delivery, FDA
Gilead Sciences, aztreonam, cystic fibrosis
NanoBio Corporation Raises $12 Million in Series B Financing
ANN ARBOR, Mich., Feb. Eighteen (HSMN NewsFeed) — NanoBio Corp., a biopharmaceutical company developing dermatological products, anti-infective treatments and intranasal vaccines, announced today that it has acquired $12 million in series B equity financing w…
Biopharmaceuticals, Venture Capital
NanoBio, NanoStat
New England Journal of Medicine Publishes Results from Boston Scientific’s Landmark SYNTAX(TM) Trial
Data show comparable safety for complex patients treated with TAXUS® Express2(TM) Stents and bypass surgery NATICK, Mass., Feb. Eighteen (HSMN NewsFeed) — Boston Scientific Corporation (NYSE: BSX ) today welcomed the publication of results from its lan…
Devices, Interventional Cardiology
Boston Scientific, TAXUS, Express2, Paclitaxel, drug eluting stent
Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
Findings Published in Peer-Reviewed Journal, Breast Cancer Research and Treatment HUNTINGTON BEACH, California, and AMSTERDAM, February Eighteen (HSMN NewsFeed) — Agendia, a world leader in molecular cancer diagnostics, today announced that a study demonst…
Diagnostics, Oncology
Agendia, MammaPrint, breast cancer, personalized medicine
Cardo Medical Announces Femur-First Versatility With Its Uni-Compartmental Knee System
LOS ANGELES, CA–Feb Eighteen, 2009 — Cardo Clinical (OTC BB:CDOM.OB ), a company engaged in the development of orthopedic pharmaceutical devices, announces the femur-first versatility in surgical technique with its Uni-Compartmental Knee System. Uni-compartmental knee…
Devices, Orthopaedic
Cardo Clinical, knee arthroplasty, Uni-Compartmental Knee
LCA-Vision Announces Appointment of Edgar F. Heizer to Board of Directors
CINCINNATI, Feb. 18 (HSMN NewsFeed) — LCA-Vision Inc. (Nasdaq: LCAV ) today announced that the Company’s Board of Directors has elected Edgar F. (Skip) Heizer, III (age 49), as a member of the Company’s Board of Directors, bringing total Board membershi…
Devices, Ophthalmology, Personnel
LCA-Vision, LasikPlus
